Your session is about to expire
← Back to Search
Study Summary
This trial will test the safety and effectiveness of a new drug, ERAS-801, for people with a certain type of brain tumor.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I have been treated with an EGFR inhibitor for my brain cancer.I have stomach or intestine problems that could affect how I absorb pills.I am currently being treated for an infection.I am 18 years old or older.My organs are working well.I can take pills by mouth.My condition is Glioblastoma, IDH wild type.I have a history of serious heart problems.
- Group 1: Dose Escalation (Part 1)
- Group 2: Dose Expansion (Part 2)
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Is this investigation enrolling participants at present?
"The clinical trial is enlisting patients, as chronicled on clinicaltrials.gov. It was initially publicized on February 25th 2022 and the most recent update to its listing occurred November 14th 2022."
Are there various sites hosting this medical experiment in the state?
"This medical research is being conducted at multiple different sites throughout the United States, including major cities such as New york and Los Angeles. For instance, Memorial Sloan Kettering Cancer Center in NY, University of California-Los Angeles in LA, and Miami Cancer Institute - Baptist Health South Florida are all hosting trials for this project. Additionally there are 7 other locations across America that are running clinical studies related to this trial."
What is the stated objective of this trial?
"This trial seeks to evaluate Dose Limiting Toxicities (DLT) over a 29 day period as its primary outcome. Subsequent objectives include gauging Plasma concentration, the amount of time required for it's peak absorption rate, and calculating ERAS-801's half life."
What criteria must one meet to be eligible for this research endeavor?
"This medical trial seeks 90 individuals aged between 18 and 99 who are diagnosed with glioblastoma. Furthermore, applicants must be able to provide informed consent, meet WHO 2021 criteria for IDH WT status, possess sufficient organ function, agree to adhere to protocol-mandated visits/assessments/procedures, and demonstrate the ability to ingest oral medication in order to qualify."
Could you outline the potential harms associated with ERAS-801 for patients?
"Due to the limited evidence supporting efficacy and safety, ERAS-801 received a score of 1."
What is the current size of the cohort participating in this trial?
"This clinical trial requires the participation of 90 eligible test subjects. Those interested can apply at locations such as Memorial Sloan Kettering Cancer Center in New york, and University of California, Los Angeles in LA."
Does the trial accept geriatric patients?
"This research is seeking participants of legal age, with the range being from 18 to 99. Separately, there are 35 trials for minors and 416 studies suitable for individuals over 65 years old."
Who else is applying?
What state do they live in?
How old are they?
What portion of applicants met pre-screening criteria?
Share this study with friends
Copy Link
Messenger